In terms of the therapeutic efficacy of SSRIs in AD, these results suggest that the effects of SERT antagonism may decline at the advanced stages of amyloidosis, in accordance with the reduction in the availability of SERT. The gene discussed is SLC6A4; the disease is Alzheimer disease.